From 2019 to 2023, Xinruipeng’s Meilian Zhonghe Animal Hospital, Barbietang Animal Hospital and other related branches were involved in the use of human drugs on animals, the use of fake veterinary drugs, and the use without radiation safety licenses. He received at least 17 administrative penalties for violations such as radiographic equipment, animal foster care activities in animal diagnosis and treatment facilities, and starting construction without submitting environmental impact reports for construction projects in accordance with the law. In addition, the company has also been involved in the "cat abuse scandal."

"Regarding (Xinruipeng) service problems, it may be related to rapid expansion, because rapid expansion may lead to challenges in service quality control, staff training, facility management, etc. ” said Bai Wenxi, Vice Chairman of China Enterprise Capital Alliance.

"The development of Xinruipeng has been strongly supported by multiple capitals. The injection of capital has accelerated the expansion of Xinruipeng, enabling it to quickly expand its market share through acquisitions and integration." Bai Wenxi said .

Bo Wenxi reminded that the rapid expansion of Xinruipeng may bring challenges to its service and quality control. At the same time, it will also bring financial and operational challenges to New Ruipeng.

In the 25th year of his business, 53-year-old Peng Yonghe finally started sprinting for IPO with Xin Ruipeng. If it successfully lands on Nasdaq in 2023, Xin Ruipeng will become "China's pet" No. 1 in the hospital." But just two months after submitting the "Prospectus", Xinruipeng has suspended the Nasdaq listing process. So far, there has been no new progress in the listing of Xin Ruipeng. Nowadays, the "hyperbaric oxygen chamber failure and murder incident" has occurred, shocking the pet lovers. How much impact will it have on the future? It's still unknown. But what is certain is that this incident will add a touch of uncertainty to its sprint into the capital market.